Skip to main content
SearchLogin or Signup

Review 1: "Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results"

This reliable study suggests four antivirals have no effect on important clinical outcomes in hospitalized COVID-19 patients. While the randomized control trial is thorough, reviewers note missing descriptions of study protocol, patient eligibility, & adverse reactions.

Published onNov 11, 2020
Review 1: "Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results"
1 of 2
key-enterThis Pub is a Review of
Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results

BACKGROUND WHO expert groups recommended mortality trials in hospitalized COVID-19 of four re-purposed antiviral drugs. METHODS Study drugs were Remdesivir, Hydroxychloroquine, Lopinavir (fixed-dose combination with Ritonavir) and Interferon-β1a (mainly subcutaneous; initially with Lopinavir, later not). COVID-19 inpatients were randomized equally between whichever study drugs were locally available and open control (up to 5 options: 4 active and local standard-of-care). The intent-to-treat primary analyses are of in-hospital mortality in the 4 pairwise comparisons of each study drug vs its controls (concurrently allocated the same management without that drug, despite availability). Kaplan-Meier 28-day risks are unstratified; log-rank death rate ratios (RRs) are stratified for age and ventilation at entry. RESULTS In 405 hospitals in 30 countries 11,266 adults were randomized, with 2750 allocated Remdesivir, 954 Hydroxychloroquine, 1411 Lopinavir, 651 Interferon plus Lopinavir, 1412 only Interferon, and 4088 no study drug. Compliance was 94-96% midway through treatment, with 2-6% crossover. 1253 deaths were reported (at median day 8, IQR 4-14). Kaplan-Meier 28-day mortality was 12% (39% if already ventilated at randomization, 10% otherwise). Death rate ratios (with 95% CIs and numbers dead/randomized, each drug vs its control) were: Remdesivir RR=0.95 (0.81-1.11, p=0.50; 301/2743 active vs 303/2708 control), Hydroxychloroquine RR=1.19 (0.89-1.59, p=0.23; 104/947 vs 84/906), Lopinavir RR=1.00 (0.79-1.25, p=0.97; 148/1399 vs 146/1372) and Interferon RR=1.16 (0.96-1.39, p=0.11; 243/2050 vs 216/2050). No study drug definitely reduced mortality (in unventilated patients or any other subgroup of entry characteristics), initiation of ventilation or hospitalisation duration. CONCLUSIONS These Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay. The mortality findings contain most of the randomized evidence on Remdesivir and Interferon, and are consistent with meta-analyses of mortality in all major trials. (Funding: WHO. Registration: ISRCTN83971151, NCT04315948)

RR:C19 Evidence Scale rating by reviewer:

  • Reliable. The main study claims are generally justified by its methods and data. The results and conclusions are likely to be similar to the hypothetical ideal study. There are some minor caveats or limitations, but they would/do not change the major claims of the study. The study provides sufficient strength of evidence on its own that its main claims should be considered actionable, with some room for future revision.


Reasoning for Strength of Evidence Rating:

The main claims made by the authors are justified, mainly because the lack of evidence of effectiveness is enough to not recommend the use of any drug. In addition, results for Hydroxychloroquine, Lopinavir/Ritonavir are consistent with those of Recovery trial (1, 2). The data of Interferon-β1a do not include relevant differences in its 95% CI. However, there are some factors that can affect reliability of results and especially the size effects found. This could be relevant for Remdesivir. Decision-makers should consider results on Hydroxychloroquine, Lopinavir/Ritonavir and Interferon-β1a as actionable. In the case of Remdesivir, the conclusion is weaker.


We agree with the authors in many of the strengths of this study, being a very good experience in the design and development of multinational, extremely pragmatic trial in a pandemic context and to be applied to any hospital around the world. However, this study shows limitations related to the design, reporting and analysis of the results.

General aspects

·      Authors should better describe the procedures for obtaining the patients’ consent to enter the trial and follow-up.

·      Both the manuscript and the protocol are very scarce in details about procedures for interim analysis: how and why the timing for interim analysis and release results were decided.

Population and randomization

·      The age of the population included in the study is lower than the age described in cohorts from Spain (3, 4), Italy (5), UK (6) and US (7). This could influence the validity of the conclusions, especially in the case of Hydroxychloroquine and Interferon-β1a, where some heterogeneity is shown in relation to age.

·      Details of the randomization procedure should be more clearly described, as it is a bit confusing.

·      One of the main problems we see is related to the pre-randomization patient selection. What it is intriguing is the different percentage of patients assigned to the different drugs in relation with the severity of the disease. Patients on oxygen at entry or already ventilated were 75.9% of those treated with Remdesivir, 63.6% of those treated with Hydroxychloroquine, 62.3% of those with Lopinavir/Ritonavir and 76.5% of those treated with Interferon-β1a. Similar differences are shown in relation with lung lesions. Also, the proportion of patients using corticosteroids in each “trial” is different (table 2, Suppl): 47.8% in “Remdesivir trial,” 14.8% in “Hydroxychloroquine trial,” 22.6% in “Lopinavir/Ritonavir trial” and 47.9% in the “Interferon-β1a trial.” We would expect that these percentages would be distributed similarly between drugs.

·      As per Figure 1, there is a substantial number of patients with no reported or no reached last follow-up. This could bias the results, mainly those of Remdesivir and Interferon-β1a.

·      It is not clear if these results can be applied to patients in early treatment of the disease, as it is difficult to know at which stage of the disease the patients were.


·      Hydroxychloroquine dose is very high. Authors should justify this and discuss the potential influence in the results, including safety issues and/or potential adverse drug reactions related to these high doses.

·      Authors should describe how oral drugs were administered in ventilated patients. It is important to account for the time from symptom initiation to start of treatment. In a clinical trial evaluating antiviral drugs we would expect that these drugs are effective only if administered in the first days after clinical onset. This would be especially relevant for Remdesivir. In the “Remdesivir trial” high risk groups have a tendency to increased mortality, although no statistical differences can be found. On the contrary, the lower risk groups could have benefit (IC99%: 0.67-1.11), an estimation similar to that found in the MTA depicted in Figure 4 (IC99%: 0.63-1.01).


·      The manuscript contains very poor description (if any) of adverse events. We recognize that with the exception of Remdesivir, this does not change the recommendation on the use of these drugs, but is a good practice to communicate as it is very important information in the benefit/risk assessment of any drug. In fact, it seems that the protocol only foresees the reporting of SUSARS.

Other aspects

·      Authors give us the results by ventilation status. However, it could be very informative to provide the subgroup analysis as in Figure 4 (No O2, low/high flow O2, ventilation) for all the drugs.

·      It would be nice if authors could provide raw data of the trial for other analysis or to be included in individual patient data meta-analysis.

Finally, this study highlights the difficulty of evaluating the repurposing of old drugs going directly from mainly theoretical arguments to highly pragmatic trials. We would need previous evidence of the activity and efficacy of these drugs to avoid dangerous short-ways in the development of new uses of old drugs.


1.     RECOVERY Collaborative Group, et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020. PMID: 33031652

2.     RECOVERY Collaborative Group, et al. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Lancet. 2020 Oct 5;396(10259):1345-1352.

3.     Borobia AM, Carcas AJ, Arnalich F et al. On Behalf Of The Covid Hulp Working Group. A Cohort of Patients with COVID-19 in a Major Teaching Hospital in Europe. J Clin Med. 2020 Jun 4;9(6):1733. doi: 10.3390/jcm9061733.

4.     Berenguer J, Ryan P, Rodríguez-Baño J et al. On behalf Of COVID-19@Spain Study Group. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain. Clin Microbiol Infect. 2020 Aug 4:S1198-743X(20)30431-6. doi: 10.1016/j.cmi.2020.07.024.

5.     Giacomelli A, Ridolfo AL, Milazzo L et al. 30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study. Pharmacol Res. 2020 Aug;158:104931. doi: 10.1016/j.phrs.2020.104931. Epub 2020 May 22.

6.     Annemarie B Docherty, Ewen M Harrison, Christopher A Green et al., ISARIC4C investigators. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020 May 22;369:m1985. doi: 10.1136/bmj.m1985.

7.     Richardson, S.; Hirsch, J.S.; Narasimhan, M.; Crawford, J.M.; McGinn, T.; Davidson, K.W.; Barnaby, D.P.; Becker, L.B.; Chelico, J.D.; Cohen, S.L.; et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020.

1 of 3

No comments here